Reading time is 2 mins


Juvenile myelomonocytic leukemia (JMML), what is juvenile myelomonocytic leukemia (JMML), usually seen in children under 2 years of age? All the details about the causes, symptoms and treatment of juvenile myelomonocytic leukemia can be found in our Turkey Health news.

Turkey Medicals – so, what is juvenile myelomonocytic leukemia (JMML)? Causes, symptoms and treatment of juvenile myelomonocytic leukemia.

Juvenile Myelomyocytic leukemia (JMML) is a rare type of blood cancer that occurs when white blood cells are severely disrupted by bone marrow production. What to know about the causes, symptoms and treatment of juvenile myelomonocytic leukemia in our news.


Juvenile myelomonocytic leukemia (JMML) is a rare chronic and aggressive type of leukemia that affects infants and young children. World Health Organization includes JMML in a group called “myelodysplastic and myeloproliferative disorders.” The average age of diagnosis of patients is around 2 years of age and is rare in children over 5-6 years of age. Boys are more common than girls.


The cause of JMML is unknown, but doctors around the world know that certain medical conditions, such as neurofibromatosis type 1 and Noonan syndrome, can increase the likelihood of a child developing it.


JMML can cause quite severe symptoms in children. These symptoms include:

  • Fever
  • Paleness
  • Bleeding (skin)
  • Infection
  • Hepatosplenomegaly (an enlarged liver and spleen)
  • Lymphadenopathy (swollen lymph nodes)
  • Recurrent lung infection
  • Erythematous maculopapular rash/xanthogranuloma (recurrent rash)
  • Bloody gayta
  • Developmental retardation
  • Central nervous system involvement (rarely)


Currently, the only potential therapeutic option is allogeneic hematopoietic stem cell transplantation, a type of bone marrow transplant. Hematopoietic stem cells are used to treat different types of blood cells (for example, blood cells)., Red blood cells, white blood cells, platelets) are special cells found in the bone marrow that produce. In allogeneic stem cell transplantation, intensive chemotherapy is given to kill JMML cells. However, healthy blood cells are also affected, and the bone marrow is essentially erased. Affected individuals then receive stem cells from another person, usually a close family member, or an unrelated donor that contains cord blood units. The transplanted cells go to the bone marrow when they begin to produce healthy blood cells. Stem cell transplants have the potential to correct the inherited genetic defect of white blood cells of individuals with JMML. However, stem cell transplantation in Antalya Turkey can cause serious, even life-threatening complications.

Graft (donor) rejection and graft-versus-host disease, bone marrow transplant procedure, including any possible complications. About 50% of children with JMML who have undergone hematopoietic stem cell transplantation will reach long-term remission. However, in about 35-40% of cases, usually within the first year, relapses will occur. In these cases, a second stem cell transplant in Antalya and Istanbul can be performed and has proven useful in many individuals.

Some individuals with JMML have undergone surgical removal of the spleen (splenectomy) as part of the treatment plan. However, the necessity and benefit of this procedure is controversial. Some researchers believe that the spleen harbors leukemia cells, which may be a potential source for relapse. However, removal of the spleen increases the risk of infection and has shown no statistical benefit in terms of the exact likelihood of recovery from the disease. Pretransplant splenectomy is not recommended unless Turkish clinically professors indicate for symptomatic relief in high-tech Turkey university hospitals.

Additional treatment is symptomatic and supportive. For example, antibiotics may be given to help prevent or fight infections in Turkish university hospitals. . .



Follow me
President of Organ Transplant Center at MedicalPark Hospital Antalya

Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.

Physician's Resume:

Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.

Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.

In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.


Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.


Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .

Professional Members:

American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.


Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.
Medically Reviewed by Professor Doctor Alper Demirbaş
Follow me